PCRX
NASDAQPacira BioSciences Inc.
Price$25.59-0.28 (-1.06%)
01:30 PM07:45 PM
News · 26 weeks93-86%
2026-01-182026-07-12
Mix5490d
- Other22(41%)
- Insider15(28%)
- SEC Filings14(26%)
- Leadership2(4%)
- Earnings1(2%)
Latest news
25 items- PRPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2026 to ten new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the "Inducement Plan") as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the "Committee") without stockholder approval. Four employees received stock options to purchase a
- PRPacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that UnitedHealthcare now provides separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) across outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This update enables EXPAREL to be reimbursed outside of the surgical bundle for eligible UnitedHealthcare members, representing an additional step i
- SECPacira BioSciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advancing the spasticity program -- -- Supports 5x30 strategy and advances Pacira’s transition into an innovative biopharmaceutical company -- BRISBANE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the divestiture of iovera ®° to Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader. The iover
- INSIDERDirector Hirawat Samit was granted 6,405 shares (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSenior Vice President, Finance Riker Lauren sold $143,702 worth of shares (6,115 units at $23.50) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 62,284 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSEC Form 4 filed by Director Wiggans Thomas G4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Christie Christopher was granted 6,405 shares, increasing direct ownership by 38% to 23,059 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Young Alethia was granted 6,405 shares, increasing direct ownership by 56% to 17,798 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Yang Michael J. was granted 6,405 shares, increasing direct ownership by 48% to 19,798 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Bigal Marcelo was granted 6,405 shares, increasing direct ownership by 56% to 17,798 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Brege Laura was granted 6,405 shares, increasing direct ownership by 27% to 30,120 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Froimson Mark was granted 6,405 shares, increasing direct ownership by 32% to 26,541 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wiggans Thomas G3 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- PRPacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual MeetingBRISBANE, Calif., June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that based on the preliminary results of its 2026 Annual Meeting of Stockholders (the "Annual Meeting") provided by its proxy solicitor, D.F. King & Co., Inc., all three of Pacira's highly qualified director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – were elected to the Board of Directors. Frank D. Lee, chief executive officer, said, "On behalf of the board and executive leadership team, I would like to express o
- INSIDERSenior Vice President, Finance Riker Lauren covered exercise/tax liability with 3,187 shares, decreasing direct ownership by 4% to 68,399 units (SEC Form 4) to satisfy withholding tax4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERChief Medical Officer Slonin Jonathan covered exercise/tax liability with 4,728 shares, decreasing direct ownership by 2% to 218,912 units (SEC Form 4) to satisfy withholding obligation4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERChief Administrative Officer Williams Kristen sold $228,468 worth of shares (10,259 units at $22.27) as part of a pre-agreed trading plan and covered exercise/tax liability with 8,528 shares, decreasing direct ownership by 10% to 167,062 units (SEC Form 4) to satisfy withholding obligation4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual MeetingElection of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward MomentumLeading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not WarrantedBRISBANE, Calif., June 4, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued a reminder to all Pacira stockholders to vote the BLUE proxy card "FOR" each of Pacira's three highly qualified director nominees in advance of the Company's upcoming 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2026. Ahea
- SECSEC Form 144 filed by Pacira BioSciences Inc.144 - Pacira BioSciences, Inc. (0001396814) (Subject)
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director NomineesISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change"BRISBANE, Calif., June 1, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS") has recommended that Pacira stockholders vote "FOR" each of Pacira's three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and "AGAINST" all three of DOMA Perpetual Ca
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Pacira's Director NomineesBRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Glass Lewis & Co., LLC ("Glass Lewis") has recommended that Pacira stockholders vote "FOR" each of Pacira's three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and "AGAINST" all three of DOMA Perpetual Capital Management LLC's ("DOMA Perpetual" or "DOMA")1 nominees on the BLUE proxy card ahead of the Company's 2026 Annual Meeting of Stockholders (the "Annual
PCRX FAQ
7 questionsWhat does Pacira BioSciences Inc. do?
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver...Where does PCRX stock trade?
Pacira BioSciences Inc. (PCRX) is listed on NASDAQ.What sector and industry is PCRX in?
Pacira BioSciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pacira BioSciences Inc. go public?
Pacira BioSciences Inc. (PCRX) completed its IPO in 2011.What are analysts saying about PCRX?
Pacira BioSciences Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $2700.00 price target on 2025-12-09. Recent price targets range from $800.00 to $3000.00.What companies are similar to PCRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PCRX side-by-side with any of them on Quantisnow.How can I track PCRX on Quantisnow?
Quantisnow aggregates Pacira BioSciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCRX to receive live email and push alerts on every new disclosure.